Considering the upper price band of Rs 51, the stock is expected to see maximum listing gains of 90% over the issue price.
However, it is important to note that grey market premiums are just an indicator as to how the company’s shares are stacked up in the unlisted market and are subject to change rapidly.
The IPO of Hamps Bio, which was completely a fresh equity sale of 21 lakh shares, received robust response from investors with a subscription of 1000 times at close.
The net proceeds from the public offer will be used for purchase of plant and machinery for FMCG division, enhancing the visibility and awareness of the brand and general corporate purposes.
Also Read: Mega multibagger! Billionaire Jhunjhunwala family makes 530x return in Inventurus IPO
Hamps Bio is engaged in the ethical marketing and distribution of pharmaceutical formulation products across a wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products.
The company is recognized in the pharmaceutical industry under its own brand name Hamps and in the freeze-dried and frozen food segment through its brand ‘FzyEzy’.
Hamps sells its products through more than 50 distributor’s networks as of October 2024 and e-commerce platforms. The company’s pharma products reach 8 states and union territories and FDFP products primarily in 6 countries.
As on the date of filing RHP, the company had a range of more than 180 different products sold across both the segments.
Also Read: 1,976x subscription! SME IPO asking for Rs 10 crore gets bids worth Rs 14,386 crore
India plays an important role in the global pharmaceuticals and vaccine industry. It is the largest provider of generic medicines globally. The country has a share of 20% in the global supply volume and contributes to around 60% of the global vaccines
For the period ended October 2024, the company clocked total revenues of Rs 4.36 crore and net profit of Rs 34 lakh.
